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Abstract
Background: The Swiss organ allocation system for donor lungs was implemented on 1 July 2007. The effects
of this implementation on patient selection, intensive care unit course, outcomes and intensive care costs are
unknown.
Methods: The first 37 consecutive lung transplant recipients following the implementation of the new act were
compared with the previous 42 lung transplant recipients.
Results: Following implementation of the new law, baseline characteristics and cumulative one-year patient survival
were comparable in both groups (88.1% vs 83.8%, P = 0.58). The costs for each case increased by 35,000 euros after
adoption of the new law. Stratifying patients after implementation of the law according to urgency status shows
that urgent patients required longer mechanical ventilation (P = 0.04), a longer ICU stay (P = 0.045) and a longer
hospital stay (P = 0.04) and ICU costs (median 64,050 euros) were higher compared to regular patients.
Conclusion: The new transplantation law has increased ICU costs with the implementation of the Swiss organ
allocation system. Patients listed as ‘urgent’ contribute significantly to the increase in ICU costs.
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Introduction
Since the first heart–lung transplant was conducted in
1980, the option of transplantation has become the
standard of care for selected patients with end-stage pul-
monary parenchymal or pulmonary vascular disorders
[1]. Initially, lung transplantation was an option for pa-
tients suffering from pulmonary vascular disorders [2]
and cystic fibrosis [3]. Since 1984, all data for heart–lung
transplantations have been recorded in the annual regis-
try of the International Society for Heart and Lung
Transplantation. Lung transplant data have been in-
cluded in this register since 1989. The main diagnoses
leading to lung transplantation are chronic obstructive
lung disease (34.6%), idiopathic pulmonary fibrosis (IPF)
(22.6%), cystic fibrosis (16.8%), α1-antitrypsin-deficiency
emphysema (6.4%) and pulmonary arterial hypertension
(3.2%) [4].
Historically, most transplantation centers used a local
allocation system. This strategy is no longer accepted by
authorities in most countries worldwide due to its lack
of transparency. In addition to increasing the number of
donor organs, countries have taken different approaches
in establishing allocation systems [5-7]. In Switzerland,
as of 1 July 2007 organs have been allocated nationwide
and no longer regionally [8]. The Swiss Organ Allocation
System (SOAS) for donor lungs is a nationwide, modi-
fied chronological system with a defined allocation
algorithm and priorities. Priority is given to patients
considered as urgent, i.e. those on mechanical ventila-
tion in an intensive care unit (ICU) or on extracorporeal
membrane oxygenator [8,9]. Secondary criteria are the
medical benefits as defined by experts followed by the
length of time waiting [8,9].
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Since 2005, the allocation of donor lungs in the United
States has been based on the lung allocation score (LAS)
[6]. This severity score is based on a model incorporat-
ing several factors predicting mortality while on the
waiting list as well as post-transplant survival. The LAS
is a composite number derived from a formula that takes
into account factors from three principal categories. The
first factor is the patient’s primary pulmonary diagnosis.
The second category relates to disease-specific factors
objectifying the disease severity (pulmonary artery pres-
sures, forced vital capacity, oxygen supplementation and
ventilator requirement). The third category addresses
the patient’s overall health outside of their pulmonary
disease (age, body mass index (BMI), New York Heart
Association functional class, PCW, 6-min walk distance,
diabetes and serum creatinine) [10]. After determining
LAS scores for individual patients, available lungs are
allocated regionally according to a prioritized ranking
based on LAS scores [10].
The effect of the implementation of the new allocation
system on lung transplantation in Switzerland in terms
of patient selection, ICU course, outcomes and costs are
analyzed in this first national single-center study. At our
institution for liver transplantation it has been demon-
strated that implementation of the MELD-based system
(model for end-stage liver disease) led to the selection of
sicker patients, increased ICU efforts and higher costs [11].
Methods
Patients
This study is a retrospective analysis of all recipients who
underwent lung transplantation at the Zurich University
Hospital between 1 January 2005 and 31 December
2008. Patients undergoing re-transplantation or combined
heart–lung transplantation (n = 6) were excluded.
We analyzed the final 42 patients (the pre-group) who
had been allocated under the regulations in effect prior
to implementation of the new allocation system on 1
July 2007, and the first 37 patients (the post-group)
under the new allocation system. In total, 79 lung trans-
plant recipients were included in this study. Following
approval by the local ethics board, all patients gave writ-
ten informed consent prior to transplantation for data
analysis after transplantation (TPL).
Demographic variables included age, sex, BMI, creatin-
ine (last value before transplantation), cytomegalovirus
status, diagnosis, time on waiting list, location immedi-
ately prior to TPL (ICU, ward or at home), need for
extracorporeal membrane oxygenation (ECMO) or
mechanical ventilation prior to TPL and evidence for
pulmonary hypertension assessed using a transthoracic
echocardiogram. Pulmonary hypertension was defined as
Doppler-calculated pulmonary arterial systolic pressure
>50 mmHg at rest [12]. Despite its limitations, this
surrogate parameter for characterization of the right
heart pre-transplant status had to be used due to the
lack of other data in the patient charts.
Operative information collected included whether the
patient underwent a unilateral or bilateral lung trans-
plantation, the cold ischemia time, need for intraopera-
tive extracorporeal circulation and transfusion levels of
red blood cells, fresh frozen plasma, thrombocytes and
fibrinogen.
Outcomes and survival
Post-operative data collected included the length of stay
(LOS) in the ICU, the readmission rate to ICU, post-
operative creatinine peak, the incidence and duration of
continuous renal replacement therapy (CRRT), the dur-
ation of mechanical ventilation and the incidence and
duration of ECMO treatment. Primary graft dysfunction,
sepsis, multiple organ dysfunction syndrome, rejection,
infection, stroke and bowel ischemia were also analyzed.
An analysis of the ICU and in-hospital mortality and
30-day and 12-month cumulative survival was per-
formed. In addition, data were collected on the duration
of hospital stay and the incidence of hemodialysis 6
months after transplantation.
Further analysis and ICU costs analysis
Days in the ICU post-transplantation, and ventilator,
CRRT and ECMO days were roughly analyzed using
local hospital cost rates for the pre- and the post-groups.
Costs are given in euros. To compare the data, a classifi-
cation of the post-group according to urgency status
(SOAS classification) and an approximated LAS score were
calculated. Due to missing data (right heart catheterization
was not routinely performed), an underestimation of the
LAS score was accepted. A stratification of patients ac-
cording to LAS quartiles was performed analogous to the
study performed by Arnaoutakis et al. [13], classifying pa-
tients into the lower 75% quartiles (Q1 to Q3) (LAS 30.1
to 44.8) and the highest quartile (Q4) (LAS 44.9 to 94.3).
Statistical analysis
The statistical analysis used SPSS Statistics Version 20
(IBM Corp, 2011). Categorical data were compared with
the Fischer’s exact test, continuous variables with the
Student’s t-test and Mann–Whitney U tests as appropri-
ate. All P values were two-sided and statistical signifi-
cance was considered as P < 0.05.
Results
The baseline characteristics of the lung transplant recipi-
ents in both cohorts are shown in Table 1. The baseline
characteristics are comparable except for a statistically
significant difference in BMI between the two groups
(P = 0.002). The change in the transplant legislation did
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Table 1 Baseline characteristics
Pre (n = 42) Post (n = 37) P value
Women 21 (50.0%) 18 (48.6%)
Men 21 (50.0%) 19 (51.4%)
Age (years) 49 (17–69) 54 (13–67) 0.34
Weight (kg) 54 (36–90) 61 (40–100) 0.008
Height (m) 1.65 (1.42–1.83) 1.65 (1.55–1.87) 0.37
BMI (kg/m2) 18.9 (14.8–34.0) 22.1 (16.0–61.0) 0.002
Creatinine (μM) 69 (29–96) 61 (31–136) 0.96
CMV positivity 18 (42.9%) 15 (40.5%) 0.84
Pulmonary hypertensiona 4 (9.5%) 5 (13.5%) 0.58
Diagnosis 0.57
CF 18 (42.9%) 11 (29.7%)
COPD 9 (21.4%) 10 (27.0%)
AAT 2 (4.8%) 3 (8.1%)
IPF 9 (21.4%) 11 (29.7%)
PAH 1 (2.4%) 0 (0%)
Other 3 (7.1%) 2 (5.4%)
Location before TPL 0.26
Home 34 (81.0%) 29 (78.4%)
Hospital, ward 6 (14.3%) 4 (10.8%)
Hospital, ICU 2 (4.7%) 4 (10.8%)
ECMO support before TPL 0 (0%) 3 (8.1%) 0.06
Mechanical ventilation before TPL 1 (4.8%) 4 (10.8%) 0.31
Data expressed as median (range) or number (percentage).
AAT, α1-antitrypsin-deficiency emphysema; BMI, body mass index; CF, cystic fibrosis; CMV, cytomegalovirus; COPD, chronic obstructive lung disease; ECMO,
extracorporeal membrane oxygenation; ICU, intensive care unit; IPF, idiopathic pulmonary fibrosis; PAH, pulmonary arterial hypertension; TPL, transplantation.
aAssessed by transthoracic echocardiography (pulmonary arterial systolic pressure > 50 mmHg) [8].
Table 2 Operative data
Intraoperative data Pre (n = 42) (%) Post (n = 37) (%) P value
ECC 17 (40.5%) 18 (48.6%) 0.47
Donor lung 0.63
Unilateral 2 (4.8%) 1 (2.7%)
Bilateral 40 (95.2%) 36 (97.3%)
EC (units) 4.6 ± 5.7 (3.0; 0–30) 4.4 ± 4.9 (3.0; 0–17) 0.67
FFP (units) 3.8 ± 6.8 (0; 0–30) 1.7 ± 3.1 (0; 0–10) 0.18
TC (units) 0.5 ± 2.5 (0; 0–16) 0.5 ± 2.0 (0; 0–12) 0.87
Fibrinogen (g) 1.1 ± 2.4 (0; 0–12) 1.7 ± 2.6 (0; 0–8) 0.28
Cold ischemia time (minutes)
Right 254 (110–404) 240 (127–420) 0.86
Left 336 (170–35) 325 (183–480) 0.91
Data are expressed as median (range), mean ± standard deviation (median; range) or number of patients (percentage).
EC, erythrocyte concentrate; ECC, extra corporeal circulation; FFP, fresh frozen plasma; TC, thrombocyte concentration.
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not significantly influence the waiting list times 121
(64-243) vs. 162 (69-311) (P = 0.56) or the diagnosis
(P = 0.57). The incidence of ECMO support before TPL
with P = 0.06 did not reach statistical significance.
There were no significant changes in post-operative
ICU data and outcomes (Table 2 and 3) following imple-
mentation of the new transplant law. Patients after im-
plementation of the new transplant law had an
unchanged LOS in the ICU (median 4 days, inter-
quartile range (IQR) 3 to 19, P = 0.14) and hospital LOS
(median 37 days, IQR 31 to 59, P = 0.45). Also the dur-
ation of mechanical ventilation remained unchanged at a
median of 2 days (IQR 1 to 17, P = 0.09) after SOAS im-
plementation. Neither the frequency of CRRT (10% to
19%, P = 0.11) nor the frequency of ECMO in the post-
operative ICU course (2% to 14%, P = 0.26) had statis-
tical significance. Likewise the frequency of ICU compli-
cations did not have any significant changes. Overall 1-
year survival was 88% before SOAS and 84% after imple-
mentation of the new transplant act.
A rough analysis of ICU costs in terms of ICU, mech-
anical ventilation (MV), CRRT and ECMO days based
on local rates revealed an increase in post-transplant
ICU costs averaging 35,000 euros/case after implementa-
tion of the new act (Table 4).
For further analysis, the post-transplant group was di-
vided into groups according to the urgency status (SOAS
classification) and LAS quartiles as described under
Methods. The baseline characteristics of this analysis
are presented in Table 5. Analyzing post-operative ICU
data and outcome according to the SOAS classification
(Table 4) revealed that urgent patients (n = 4) required
a longer ICU LOS (P = 0.045), a longer hospital LOS
(P = 0.04) and increased duration of MV (P = 0.04), while
the frequency of CCRT (18% vs 25%) and ECMO (9% vs
50%) did not have statistical significance. One-year sur-
vival in the regular group was comparable to urgent
patients (82% and 100%, respectively). Analysis of data
according to LAS quartiles showed similar results: pa-
tients in the highest LAS quartile (n = 8) required a
Table 3 ICU data
Pre (n = 42) Post (n = 37) P value
ICU post TPL (days) 9.5 ± 13.1 (4; 2–66) 17.5 ± 32.5 (4; 2–148) 0.14
Mechanical ventilation post TPL (days) 5.7 ± 9.2 (2; 1–42) 14.6 ± 32.8 (2; 1–148) 0.09
Creatinine peak (μmol/l) 103 (47–395) 95 (56–357) 0.51
CRRT 4 (9.5%) 7 (18.9%) 0.23
CRRT post TPL (days) 1.8 ± 9.6 (0; 0–62) 8.4 ± 31.1 (0; 0–126) 0.19
Readmission to ICU 6 (14.3%) 3 (8.1%) 0.39
ICU stay including readmission (days) 10.1 ± 14.7 (4.5; 2–79) 21.9 ± 42.0 (5; 2–181) 0.10
Mechanical ventilation including readmission (days) 6.2 ± 10.2 (2; 1–45) 18.7 ± 40.1 (2; 1–161) 0.06
CRRT including readmission (days) 2.3 ± 11.6 (0; 0–75) 12.1 ± 37.3 (0; 0–144) 0.11
ECMO 1 (2.4%) 5 (13.5%) 0.05
ECMO after TPL (days) 0.1 ± 0.8 (0; 0–5) 1.5 ± 4.9 (0; 0–22) 0.04
Primary graft dysfunction 5 (11.9%) 6 (16.2%) 0.58
Acute rejection 1 (2.4%) 1 (2.7%) 0.93
Sepsis 3 (7.1%) 6 (16.2%) 0.02
MODS 5 (11.9%) 5 (13.5%) 0.83
Infection 6 (14.3%) 7 (18.9%) 0.58
Stroke 2 (4.8%) 0 (0%) 0.18
Bowel ischemia 2 (4.8%) 4 (10.8%) 0.31
ICU mortality 3 (7.1%) 2 (5.4%) 0.75
Hospitalization days 41 ± 25.6 (36.5; 3–169) 58.2 ± 51.4 (36; 20–270) 0.45
In-hospital mortality 4 (9.5%) 5 (13.5%) 0.58
IHD 6 months post TPL 1 (2.4%) 2 (5.4%) 0.48
Survival 30 days 39 (92.9%) 36 (97.3%) 0.37
Survival 1 year 37 (88.1%) 31 (83.8%) 0.58
Data are expressed as median (range), mean ± standard deviation (median; range) or number (percentage).
CRRT, continuous renal replacement therapy; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; IHD, intermittent hemodialysis; MODS,
multiple organ dysfunction syndrome; TPL, transplantation.
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significantly longer ICU stay (P = 0.01), longer duration
of MV (P = 0.007) as well as more ECMO days (P = 0.02)
with comparable 1-year survival between the highest
LAS quartile and the other quartiles (86% and 75%, re-
spectively). The rough ICU cost analysis according to
SOAS urgency status and LAS quartile is presented in
Table 5. While the difference in total ICU costs between
regular and urgent patients (median 8,500 euros vs
64,050 euros) did not reach statistical significance (P =
0.05), the difference in ICU costs between the lowest
75% LAS quartiles and the highest LAS quartile (median
8,500 euros vs 47,750 euros) was statistically significant
(P = 0.02).
Discussion
This is the first study to evaluate the effect of the imple-
mentation of the Swiss Organ Allocation System on ICU
outcomes and resource utilization. For this purpose the
final 42 patients before and the first 37 patients after im-
plementation of the law on 1 July 2007 were analyzed in
this retrospective study.
While baseline characteristics and outcome were com-
parable between the two cohorts of lung transplant pa-
tients, the implementation of the law led to a marked
increase in post-transplantation ICU costs of approxi-
mately 35,000 euros/case. A further analysis of patients
allocated after implementation of the law indicates that
treatment for patients listed as urgent according to
SOAS differed from patients listed as regular: urgent pa-
tients required a five times longer median ICU stay after
TPL and twice as long median hospital stay as well as
significantly longer mechanical ventilation after TPL.
This led to a significant increase in ICU charges: median
costs increased by a factor of seven. Patients were strati-
fied into the highest and lowest 75% LAS quartiles for
comparison with international data: patients in the high-
est LAS quartile required a significantly longer ICU LOS
and significantly longer duration of mechanical ventila-
tion and ICU costs were significantly higher.
The implementation of SOAS with a change from
center-orientated allocation to national allocation did
not increase the cold ischemia time of donor lungs, as
seen from a comparison of the pre- and post-groups.
Since an increased incidence of organ transportation has
to be expected with the change in allocation, an eventual
effect on cold ischemia time and presumably a negative
effect on outcomes have to be considered. Data pub-
lished by Immer and colleagues for Swisstransplant
showed an increased frequency in organ transportation
after implementation of the new transplantation act for
all organs [14]. For donor lungs, the transplantation fre-
quency at the site of procurement decreased from 21.2%
to 7.3% [14]. In agreement with our data, no significant
influence on cold ischemia time nationwide was found.
Our study did not register the origin of the donor lung,
but traditionally the Zurich area has a low organ donor
rate [8] so it can be assumed that the percentage of lung
transplantations performed with organs donated from a
different part of Switzerland remained unchanged and
thus there was no change in the cold ischemia time. Ac-
cording to Swisstransplant’s annual report for 2012, 52
lung transplantations were performed in two centers
(of which 33 were in Zurich) from 96 multi-organ do-
nors [8]. Overall waiting list times in Zurich were not af-
fected after the implementation of the new transplant
act in the period analyzed in this study. Of note, the util-
ity rate of lung donors in Switzerland was 52% in 2012 [8],
which is high compared to international data and might
influence the early post-operative outcomes and costs.
Concerning the diagnosis leading to transplantation,
there was no statistically significant difference between
the two cohorts. The second and third priority diagno-
ses, pulmonary hypertension and IPF, did not have a sta-
tistically significant influence. However, there was an
increase in lung transplantations performed for IPF from
21.4% to 29.7%. This finding is in accord with inter-
national data, which shows that there has been a steady
increase in the number of transplant procedures for IPF
during the last decade, reaching almost 30% of all proce-
dures performed [4]. The incidence of cystic fibrosis in
our small Swiss cohort (overall 37%) is rather high com-
pared to international data (16.8%) [4].
Cost estimations for transplantations are difficult and
complex. There are limited data on the estimation of
costs for lung transplant patients [15-17]. Our institu-
tion recently published our single-center experience
concerning liver transplantation after the new trans-
plantation act was implemented [11]. The results show
markedly increased costs per transplantation. Those
findings were explained because there were higher
MELD scores for patients prior to transplantation, caus-
ing an increase in pre-transplant costs as well as an in-
crease in post-transplant ICU costs.
The implementation of the high-priority urgent status
assigned to patients on invasive mechanical ventilation
Table 4 Calculation of ICU costs
Pre (n = 42) Post (n = 37) P value
ICU (days; euros) 441; 882,000 810; 162,0000 0.37
Ventilation (days; euros) 263; 132,000 691; 345,500 0.52
CRRT (days; euros) 96; 38,000 437; 174800 0.32
ECMO (days; euros) 5; 5,000 85; 85,000 0.20
Σ ICU costs (euros) 1,057,000 2,225,000
Σ ICU costs per case (euros) 25,000 60,000
Difference per case (euros) 35,000
CRRT, continuous renal replacement therapy; ECMO, extracorporeal membrane
oxygenation; ICU, intensive care unit.
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Table 5 Estimation of ICU costs
Transplantation law SOAS classification LAS quartile
Pre (n = 42) Post (n = 37) P value Regular Urgency P value Q1 to Q3 Q4 P value
ICU (euros) 10,000 (7,000–22,500) 10,500 (7,000–49,000) 0.76 8,000 (6,000–28,000) 39,000 (26,000–61,000) 0.07 8,000 (6,000–10,000) 39,000 (21,000–61,000) 0.02
MV (euros) 1,000 (500–3,500) 1,000 (500–9,000) 0.88 500 (500–6,500) 8,500 (6,500–9,000) 0.06 500 (500–1,000) 8,750 (4,250–13,750) 0.01
ECMO (euros) 5,000 (5,000–5,000) 15,000 (15,000–22,000) 0.67 15,000 (2,000–15,000) 26,500 (22,000–31,000) 0.2 8,500 (2,000–15,000) 22,000 (15,000–31,000) 0.3
Total ICU costs 10,000 (7,000–22,500) 10,500 (7,000–49,000) 0.82 8,500 (6,500–35,400) 64,050 (34,500–81600) 0.05 8,500 (6,500–11,000) 47,750 (25,250–102,050) 0.02
Data are median (IQR).
ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; MV, mechanical ventilation.
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in the ICU did not have a statistically significant influ-
ence after implementation of the new law. However, the
analysis of the post-group shows that urgent patients
and those in the highest LAS quartile suffered a pro-
longed transplantation course in terms of LOS in the
hospital and ICU and mechanical ventilation. This
caused a marked increase in ICU costs.
Arnatoukis et al. recently examined the effect of the
implementation of LAS on resource utilization and costs
[13]. They showed that there was a marked increase in
costs for patients in the highest LAS quartile, primarily
due to an increase in ICU and hospital days and the dur-
ation of mechanical ventilation. Patients with high LAS
scores are critically ill [18] with comorbidities. The re-
sults of our analysis are in accord with the results of
Arnatoukis et al. [13]: more critically ill patients pro-
ceeding for transplantation leads to an increase in hos-
pital and ICU days, days on mechanical ventilation and
overall post-transplant ICU costs. In addition, the trend
for the increased use of ECMO is leading to an increase
in costs.
The value of ECMO support has been extensively de-
bated since the results of the CESAR trial in 2009 [19].
Similarly, attitudes toward using ECMO for respiratory
failure in lung transplant candidates have changed over
time. The indication for ECMO is no longer limited to
‘bridge to recovery’ as a desperate maneuver, but has
established indications as ‘bridge to transplant’ and
‘bridge to improvement’ [20-22] in the pre-transplant
and post-transplant phases, respectively. Internationally,
ECMO is being implemented at an earlier stage. Several
centers have reported their first experiences with ECMO
for non-intubated patients [23,24]. The increased use of
ECMO is presumably due to this international develop-
ment and proven indication.
No difference in 1-year survival was detected between
the cohorts for before and after implementation of the
law, nor for patients listed as urgent or regular in the post-
group. Due to our small sample size, this study might very
well be underpowered to detect a difference in survival
and the results of a larger cohort study are awaited.
Initial experiences from France with high-emergency
lung transplantation showed there was poorer post-
transplant survival of these patients compared to regular
lung transplant recipients [25], so the further develop-
ment of the necessity for mechanical ventilation before
transplantation has to be assessed.
The main limitation of this retrospective analysis is the
low number of patients included, which limits the statis-
tical power of the results.
Conclusion
In conclusion, the implementation of the new transplant
law has so far led to increased ICU costs. In particular,
patients listed as urgent seem to have a prolonged post-
operative ICU and hospital course.
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